Key Highlights

  • Arcadia Biosciences (NASDAQ:RKDA) was trading down 7.21% at USD 0.2060 in pre-market on Friday, November 13, 2026, and no company announcement dated November 11 to 13 explaining the move was found.
  • The shares closed at USD 0.1450 on October 19, 2026 in published data, so USD 0.2060 is about 42% higher (calculated), which frames the dip as a pullback within a volatile range.
  • The 52-week range ran from USD 0.1110 to USD 5.2290 in published data, with about 2.41 million shares outstanding and a market cap near USD 349,000 at the October price.
  • The planned Business combination with Roosevelt Resources was terminated in December 2025, and the company closed a USD 4 million private Placement on June 13, 2026.

Dip Follows a Rebound, With No New Announcement Found

Arcadia Biosciences (NASDAQ:RKDA) was trading down 7.21% at USD 0.2060 in pre-market on November 13, 2026, according to pre-market market data. The implied prior close is about USD 0.2220 (calculated), far above the USD 0.1450 close of October 19, when the stock fell 12.01%. No press release or filing dated November 11 to 13 explaining either swing was found. In a sub-USD 1 stock, a small number of trades can move the price, spreads can be wide and quoted moves can reverse. The screener's prior close can be stale for micro caps, so the 7.21% is a pre-market figure only. On October 20 the pre-market price in published data was USD 0.1363, which shows how widely the quote has ranged in a few weeks.

Zola, Wheat Traits and a Terminated Merger

Arcadia develops wheat crop improvements and sells consumer products including Zola coconut water, GoodWheat and ProVault. In 2025 the company planned an all-stock combination with Roosevelt Resources, but it announced termination on December 26, 2025 and confirmed it with full-year results on March 26, 2026. For the third quarter of 2025, Revenue was USD 1.30 million against USD 1.54 million, with cash of USD 1.1 million. Zola volumes rose 18% year over year in the first quarter of 2026, according to the company release. Gross Margin exceeded 30% for 11 straight quarters through the third quarter of 2025, but the company is small, with only a handful of employees, and a few customers can swing volumes in a quarter.

Private Placement, Resale Registration and Dilution Risk

The company announced a USD 4 million private placement on June 12, 2026, priced at the market under Nasdaq rules, and closed it on June 13. A published summary put cash near USD 4.2 million at the end of the second quarter, with operating cash use of USD 319,000, though that figure comes from a single summary. Published data also showed a registration for the resale of 11.92 million shares, which conflicts with the 2.41 million shares listed as outstanding, so the share count is unreconciled. Third-quarter results for 2026 were not found, and Nasdaq listing, dilution and Liquidity are the main risks.

Where Things Stand

The dip looks like Volatility after a rebound rather than a company-announced event. Arcadia Biosciences (NASDAQ:RKDA) was trading down 7.21% at USD 0.2060 in pre-market on November 13, 2026, still about 42% above the October 19 close, and no catalyst was found. The business is small, with trailing revenue near USD 4.75 million and a recent USD 4 million placement. Next markers are the third-quarter report, any resale of registered shares and any Nasdaq compliance notice.